F
Francisco Conejero-Lara
Researcher at University of Granada
Publications - 64
Citations - 1287
Francisco Conejero-Lara is an academic researcher from University of Granada. The author has contributed to research in topics: Protein folding & Heptad repeat. The author has an hindex of 19, co-authored 60 publications receiving 1128 citations. Previous affiliations of Francisco Conejero-Lara include Spanish National Research Council & University of Oxford.
Papers
More filters
Book ChapterDOI
Preparation and Investigation of Crucial Oligomers in the Early Stages of Aβ40 and Aβ42 Aggregation.
TL;DR: In this paper , the authors describe detailed methods for the preparation and isolation of micellar oligomers of Aβ that evolve towards larger and more stable oligomers enriched in beta-sheet structure and able to acquire higher capacity to fibrillate.
Patent
Immunological compositions against hiv
Francisco Conejero-Lara,Irene Luque,Pedro L. Mateo,Andreas Wagner,Raphaelle Claude,Marie-Gaëlle Roger,Nicolas Mouz,Christophe Martin +7 more
TL;DR: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV) as mentioned in this paper, which is a vaccine-resistant strain of the virus.
Journal ArticleDOI
Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins
Daniel Polo-Megías,Mario Cano-Muñoz,Alberto G. Berruezo,Géraldine Laumond,Christiane Moog,Francisco Conejero-Lara +5 more
TL;DR: In this paper , the authors describe the design and characterization of chimeric proteins that structurally imitate the S2 HR1 region in a trimeric coiled-coil conformation, and determine their capacity to bind the HR2 region, as well as their inhibitory activity of SARS-CoV-2 infection in vitro.
Patent
Immunological compositions comprising hiv gp41 polypeptide derivatives
Francisco Conejero-Lara,Irene Luque,Pedro L. Mateo,Andreas Wagner,Raphaelle Claude,Marie-Gaëlle Roger,Nicolas Mouz,Christophe Martin +7 more
TL;DR: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV) as mentioned in this paper, which is a type of vaccine.